🔎 Trials Near Me

Home › Prostate Cancer › NCT07526545

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

RecruitingHealthy volunteers welcome

UPRISE (Urine Prostate Screening Integrated With MRI for Prostate Cancer Early Detection)

Who can join

Ages 50 to 75 · Men · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria:

* Males aged 50-75
* PSA 3-20 ng/ml within the previous 3 months
* Fit to undergo all procedures listed in protocol per treating physician's discretion
* No prostate biopsy in the past 4 years
* No prostate MRI in the past 2 years
* Able to provide written informed consent

Exclusion Criteria:

* Prior diagnosis of prostate cancer
* Contraindication to MRI (e.g. claustrophobia, pacemaker)
* Contraindication to prostate biopsy
* Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work

About the study

This clinical trial tests how well a urine prostate cancer screening test, My Prostate Score 2 (MPS2), integrated with magnetic resonance imaging (MRI) works for early detection of prostate cancer. MPS2 is an investigational urine-based test designed to help identify the likelihood of having aggressive prostate cancer. MPS2 testing works by measuring specific early detection biomarkers that include genetic information. This next-generation test aims to address a major challenge in prostate cancer care-detecting only the cancers that truly need treatment. Results may lead to paradigm shifts in early detection algorithms and reduce reliance on MRI and biopsy.

What is being tested

Sponsor: University of Michigan Rogel Cancer Center · Participants: 800 · Started: Dec 1, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07526545

Locations in the U.S.

MichiganUniversity of Michigan Rogel Cancer Center, Ann Arbor

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.